

ASTCT Pharmacy SIG Journal Club Session

June 7, 2023

2-3 PM CST

TARGET AUDIENCE

This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing allogeneic stem cell transplant.

PROGRAM OVERVIEW

This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q&A session. In the June Journal Club session, Drs. Chen and Scott will present on two articles related to the use of (a) defibrotide for prophylaxis of sinusoidal obstruction syndrome and (b) allogeneic transplant in newly diagnosed patients with AML following venetoclax/azacitidine or intensive induction. This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing allogeneic stem cell transplant.

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

- Describe current standards of care in the prevention of sinusoidal obstruction syndrome
- Evaluate the safety and efficacy of defibrotide use for the prevention of sinusoidal obstruction syndrome
- Compare sinusoidal obstruction syndrome outcomes in patients that received defibrotide plus standard of care standard versus care alone
- Summarize the role of venetoclax plus azacitidine in the treatment of patients with newly diagnosed acute myeloid leukemia
- Compare post-allogeneic hematopoietic stem cell transplant outcomes between patients who received initial induction with venetoclax plus azacitidine or an intensive chemotherapy regimen

FACULTY & ARTICLES

Teaghan Chen, PharmD

PGY-2 Pharmacy Resident

Children's Hospital Colorado

[Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome \(harmony\): a randomised, multicentre, phase 3 trial](#)

Campbell Scott, PharmD

PGY-2 Pharmacy Resident

University of Georgia

[Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy](#)

Instructions for Participation and Requesting Credit

There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity, and completing the post-test and evaluation form.

Credit Fulfillment

- If you are a pharmacist requesting ACPE credits, your credit request will be uploaded to CPE Monitor within 60 days.

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists



This knowledge-based activity, UAN # JA0007204-9999-23-037-L01-P, qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit. **Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date.** Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other healthcare professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Disclosures

The individuals listed below disclosed the following relevant financial relationships:

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Campbell Scott, PharmD	Faculty	No relevant financial disclosures	NA	NA
Haedyn Smith	ASTCT Staff	No relevant financial disclosures	NA	NA
Teaghan Chen, PharmD	Faculty	No relevant financial disclosures	NA	NA

DISCLOSURE OF UNLABELED USE

TFF and ASTCT require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

MEDIA DISCLOSURE

Your registration, attendance at, and/or participation in this meeting constitutes consent to being photographed, videotaped, or recorded during the meeting by The France Foundation, its educational collaborators, or anyone authorized on behalf of these organizations. You further authorize, without any compensation paid to you, the use of any photographs, videos, or recordings that contain your likeness, image, or voice in any educational, informational, commercial, or promotional materials produced and/or distributed by The France Foundation, its educational collaborators, or anyone authorized by these organizations, as well as on any internet sites maintained by any of these entities. Images/recordings used for these purposes will not be sold, and no personal information about you or the subject (other than event location and date) will be included in the production of any material.

DISCLAIMER

TFF and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and ASTCT assume no liability for the information herein.

CONTACT INFORMATION

If you have questions about this CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.